Almirall (LBTSF) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Almirall LBTSF is currently developing the following drugs: Lad603, Lad191, Adalimumab, Lebrikizumab, Lad191, Vehicle Ointment, Tirbanibulin, Tirbanibulin 2.5 Mg Ointment, Tirbanibulin (Klisyri®) 10 Mg/G Ointment, Diclofenac Sodium 3% Gel, Tirbanibulin Ointment 1%, Tildrakizumab, Pidotimod, Tildrakizumab, Dimethyl Fumarate (Dmf) Standard Scheme, Dimethyl Fumarate (Dmf) Simplified Scheme, Tildrakizumab 100 Mg Solution For Injection, Kx2-391 Ointment 1%, P-3058 (Terbinafine Hydrochloride 10%), Vehicle Of P-3058, P-3073 (Calcipotriene 0.005%), Vehicle Of P-3073, Dapsone Gel, Las41008 120 Mg / Fumaderm® 120 Mg, 50 Mg Of Kx2-391 Ointment 1%, Sarecycline, Vehicle, 5-Fluorouracil/Salicylic Acid, Dapsone Gel, Dapsone Gel Vehicle, Dapsone Gel, Normal Saline, Dapsone Gel Vehicle, Sodium Lauryl Sulfate, Las41008, Lasw1835, 50 Mg P005672-Hcl, 100 Mg P005672-Hcl. These drug candidates are in various stages of clinical development as the company works toward FDA approval.